CT829 : A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18-75Age 18-75

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Head and neck,Skin,Stomach and upper gastrointestinal tractAnus,Basal cell carcinoma,Bile duct,Colon,Colorectum,Cutaneous Squamous Cell Carcinoma (CSCC),Gallbladder,Gastro-oesophageal junction ,Liver,Melanoma (Ocular),Melanoma (Skin),Merkel cell,Nose (nasopharynx),Oesophagus,Oral cavity,Oropharynx,Pancreas,Rectum,Salivary glands,Stomach,Throat (hypopharynx),Thyroid,Voice box (larynx)

Trial Overview Read MoreRead more

This phase I/II trial is evaluating two drugs (ribociclib and trametinib) for the treatment of advanced cancers (excluding blood cancer).
 

This trial is treating multiple types of cancer including Pancreatic, Colorectal, Other solid cancers (excluding blood).

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors

Commercial Sponsor

Novartis Pharmaceuticals

Summary

Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.

Not Recruiting Hospitals Read MoreRead more

Closed

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next